Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease.

por Pizzolo, G., Chilosi, M., Semenzato, G., Caligaris-Cappio, F., Fiore-Donati, L., Perona, G., Janossy, G.
Publicado 1984

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

por Gregorc, V, Santoro, A, Bennicelli, E, Punt, C J A, Citterio, G, Timmer-Bonte, J N H, Caligaris Cappio, F, Lambiase, A, Bordignon, C, van Herpen, C M L
Publicado 2009

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

por Santoro, A, Pressiani, T, Citterio, G, Rossoni, G, Donadoni, G, Pozzi, F, Rimassa, L, Personeni, N, Bozzarelli, S, Rossoni, G, Colombi, S, De Braud, F G, Caligaris-Cappio, F, Lambiase, A, Bordignon, C
Publicado 2010

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

por Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C
Publicado 2018